Pharmacological management of type 2 diabetes mellitus: Rationale for rational use of insulin

Mayo Clinic Proceedings

Volumn 78, Issue 4, 2003, Pages 459-467

  Chan, Ean L ^a   Abrahamson, Martin J ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; CHLORPROPAMIDE; GLARGINE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; GLUCOSE; HEMOGLOBIN A1C; HUMALOG MIX 75/25; HUMAN INSULIN; HUMULIN 70/30; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; NOVOLIN 70/30; NOVOLOG MIX 70/30; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

DIABETIC DIET; DIABETIC MICROANGIOPATHY; DISEASE COURSE; DRUG ABSORPTION; DRUG MECHANISM; EXERCISE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOTOXICITY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RESISTANCE; INSULIN TREATMENT; LIPOTOXICITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; PATHOPHYSIOLOGY; REVIEW;

EID: 0037380061     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/78.4.459     Document Type: Review

References (78)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-1431.
2. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol. 1997;146:214-222.
3. Riddle MC. Tactics for type II diabetes. Endocrinol Metab Clin North Am. 1997;26:659-677.
4. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
5. Bjork S. The cost of diabetes and diabetes care. Diabetes Res Clin Pract. 2001;54(suppl 1):S13-S18.
6. Egede LE, Zheng D. Modifiable cardiovascular risk factors in adults with diabetes: prevalence and missed opportunities for physician counseling. Arch Intern Med. 2002;162:427-433.
7. Palumbo PJ. Glycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus. Mayo Clin Proc. 2001;76:609-618.
8. Nathan DM. Prevention of long-term complications of non-insulin-dependent diabetes mellitus. Clin Invest Med. 1995;18:332-339.
9. Skyler JS. Diabetic complications: the importance of glucose control. Endocrinol Metab Clin North Am. 1996;25:243-254.
10. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996;124(1, pt 2):90-96.
11. Kahn SE, Porte D Jr. The pathophysiology of type II (noninsulin-dependent) diabetes mellitus: implications for treatment. In: Porte D Jr, Sherwin RS, eds. Ellenberg & Rifkin's Diabetes Mellitus. 5th ed. Stamford, Conn: Appleton & Lange; 1997:487-512.
12. Porte D Jr, Banting lecture 1990: β-cells in type II diabetes mellitus. Diabetes. 1991;40:166-180.
13. Porte D Jr, Kahn SE. β-Cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes. 2001;50(suppl 1):S 160-S163.
14. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 1992;15:318-368.
15. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med. 2002;113(suppl 6A):3S-11S.
16. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992;15:815-819.
17. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787-794.
18. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24:89-94.
19. Turner RC, Cull CA, Frighi V, Holman RR, UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
20. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease [published correction appears in Diabetes. 1996;45:1655] Diabetes. 1995;44:1249-1258.
21. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
22. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2001;24(suppl 1):S33-S43.
23. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract. 2002;8(suppl 1):5-11.
24. Hamdy O, Goodyear LJ, Horton ES, Diet and exercise in type 2 diabetes mellitus. Endocrinol Metab Clin North Am. 2001;30:883-907.
25. Klein S. Outcome success in obesity. Obes Res. 2001;9(suppl 4):354S-358S.
26. Knowler WC, Barrett-Connor E, Fowler SE, et al, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
27. UKPDS Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients. Metabolism. 1990;39:905-912.
28. Dunn CJ, Faulds D. Nateglinide. Drugs. 2000;60:607-615.
29. Lebovitz HE. Insulin secretagogues: sulfonylureas and repaglinide. In: Lebovitz HE, ed. Therapy for Diabetes Mellitus and Related Disorders. 3rd ed. Alexandria, Va: American Diabetes Association; 1998:160-170.
30. Beckey NP. Diabetes mellitus therapy: evaluating the role of the newer antidiabetic agents. Formulary. 1998;33:858-881.
31. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
32. Rosiglitazone for type 2 diabetes mellitus. Med Lett Drugs Ther. 1999;41:71-73.
33. Gillies PS, Dunn CJ. Pioglitazone. Drugs. 2000;60:333-343.
34. Riddle MC. Oral pharmacologic management of type 2 diabetes. Am Fam Physician. 1999;60:2613-2620.
35. Purnell JQ, Hirsch IB. New oral therapies for type 2 diabetes. Am Fam Physician. 1997;56:1835-1842.
36. Feinglos MN, Bethel MA. Oral agent therapy in the treatment of type 2 diabetes. Diabetes Care. 1999;22(suppl 3):C61-C64.
37. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am. 1997;26:511-522.
38. Zangeneh F, Kudva YC, Basu A. Insulin sensitizers. Mayo Clin Proc. 2003;78:471-479.
39. Bergenstal RM, Kendall DM, Franz MJ, Rubenstein AH. Management of type 2 diabetes: a systematic approach to meeting the standards of care. II: oral agents, insulin, and management of complications. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 4th ed. Philadelphia. Pa: WB Saunders Co; 2001:821-835.
40. Garber AJ, Piper BA, Park J-S. Durable anfidiabetic effect of glyburide/metformin tablets as initial therapy for type 2 diabetes [abstract]. Diabetes. 2001;50(suppl 2):A113. Abstract 451-P.
41. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
42. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23:1660-1665.
43. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:119-124.
44. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL, Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2000;22:1395-1409.
45. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial [published correction appears in JAMA. 2000;284:1384]. JAMA, 2000;283:1695-1702.
46. Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study [published correction appears in Diabet Med. 2000;17:332]. Diabet Med. 1999;16:755-761.
47. Phillips P, Karrasch J, Scott R, Wilson D, Moses R. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care. 2003;26:269-273.
48. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW, Troglitazone Study Group. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care. 1998;21:1462-1469.
49. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111:10-17.
50. Francis AJ, Home PD, Hanning I, Alberti KG, Tunbridge WM. Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast. Br Med J (Clin Res Ed). 1983;286:1173-1176.
51. Bolli GB, Perriello G, Fanelli CG, De Feo P. Nocturnal blood glucose control in type I diabetes mellitus. Diabetes Care. 1993;16(suppl 3):71-89.
52. Lindstrom T, Olsson PO, Arnqvist HJ. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles. Scand J Clin Lab Invest. 2000;60:341-347.
53. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999;42:1151-1167.
54. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-2148.
55. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:644-649.
56. Burge MR, Schade DS. Insulins. Endocrinol Metab Clin North Am. 1997;26:575-598.
57. Barnett AH, Owens DR. Insulin analogues [published correction appears in Lancet. 1997;349:656]. Lancet. 1997;349:47-51.
58. Hedman CA, Lindstrom T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes [letter]. Diabetes Care. 2001;24:1120-1121.
59. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999;22:403-408.
60. Abrahamson MJ. Expediting the paradigm shift: the role of comprehensive oral therapy. Paper presented at: Managing Outcomes in Type 2 Diabetes Summit Meeting; New York, NY; June 19, 2000.
61. Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin: a multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001; 134(9, pt 1):737-745.
62. Groop LC, Widen E, Ekstrand A, et al. Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM. Diabetes Care. 1992;15:831-834.
63. Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med. 1999;130:389-396.
64. Yki-Järvinen H, Dressler A, Ziemen M, HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000;23:1130-1136.
65. Riddle MC, Rosenstock J, HOE901/4002 Study Group. Treatment to target study: insulin glargine vs NPH insulin added to oral therapy of type 2 diabetes: successful control with less nocturnal hypoglycemia [abstract]. Diabetes. 2002;51(suppl 2):A113. Abstract 457-P.
66. Rosenstock J, Riddle MC, HOE901/4002 Study Group. Treatment to target study: timing and frequency of nocturnal hypoglycemia: the value of adding bedtime basal insulin glargine over NPH insulin in insulin-nayve patients with type 2 diabetes on oral agents [abstract]. Diabetes. 2002;51(suppl 2):A482. Abstract 1982-PO.
67. Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131:182-188.
68. Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW, Troglitazone Insulin Study Group. Troglitazone use in insulin-treated type 2 diabetic patients. Diabetes Care. 1998;21:1455-1461.
69. Schwartz S, Raskin P, Fonseca V, Graveline JF, Troglitazone and Exogenous Insulin Study Group. Effect of troglitazone in insulintreated patients with type II diabetes mellitus. N Engl J Med. 1998;338:861-866.
70. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J, Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24:1226-1232.
71. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S, Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002;56:251-257.
72. McSorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther. 2002;24:530-539.
73. Roach P, Strack T, Arora V, Zhao Z. Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. Int J Clin Pract. 2001;55:177-182.
74. NovoLog Mix 70/30 [product information]. Princeton, NJ: Novo Nordisk Pharmaceuticals, Inc; 2002.
75. Humalog Mix 75/25 [product information]. Indianapolis, Ind: Eli Lilly and Company; 2001.
76. Humalog. Physicians' Desk Reference. 56th ed. Montvale, NJ: Medical Economics Co; 2002:1926-1928.
77. Ohkubb Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
78. Fanelli CG, Pampanelli S, Porcellati F, Rossetti P, Brunetti P, Bolli GB. Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control: a randomized, controlled trial. Ann Intern Med. 2002;136:504-514.